Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical UpdatesGlobeNewsWire • 05/03/23
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)GlobeNewsWire • 04/27/23
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023GlobeNewsWire • 04/19/23
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric EndocrinologyGlobeNewsWire • 03/05/23
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development UpdatesGlobeNewsWire • 03/01/23
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHDGlobeNewsWire • 02/28/23
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023GlobeNewsWire • 02/15/23
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023GlobeNewsWire • 01/03/23
KOL Review of Lumos Pharma's Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD PatientsGlobeNewsWire • 12/12/22
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHDGlobeNewsWire • 11/29/22
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare ConferenceGlobeNewsWire • 11/22/22
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development UpdatesGlobeNewsWire • 11/14/22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone DeficiencyGlobeNewsWire • 11/14/22
Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development UpdatesGlobeNewsWire • 08/09/22
Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 08/02/22
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022GlobeNewsWire • 07/27/22
Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22